Zobrazeno 1 - 10 of 29 pro vyhledávání: '"Gillian A. Horne"'
1
Akademický článek
Targeting BCR-ABL1-positive leukaemias: a review article
Autor: Steven Leak, Gillian A. Horne, Mhairi Copland
Publikováno v: Cambridge Prisms: Precision Medicine, Vol 1 (2023)
Treatment and understanding of BCR::ABL1-positive leukaemias is a precision medicine success story. Our appreciation of the BCR::ABL1 gene and resulting BCR::ABL1 oncoprotein in chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive (Ph
Externí odkaz: https://doaj.org/article/a70ea6d17f204730819a0a072a3a0532
Zobrazit plný text záznamu
2
A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease
Autor: Annie Latif, Arunima Mukhopadhyay, Mhairi Copland, Fiona Thomson, Dragana Milojkovic, Letizia Foroni, G. M. Smith, Jenny Byrne, Gillian A. Horne, Paolo Gallipoli, Philippe Schafhausen, Judith Dixon-Hughes, Franck E. Nicolini, P. Cony-Makhoul, Richard E. Clark, Wenjuan Cong, Gudmundur Vignir Helgason, Jon Stobo, Steffen Koschmieder, T H Brümmendorf, Lynn McMahon, Caroline Kelly, Tessa L. Holyoake
Publikováno v: Leukemia
LEUKEMIA
Horne, G, Stobo, J, Kelly, C, Mukhopadhyay, A, Latif, A, Dixon, J, McMahon, L, Cony-Makhoul, P, Byrne, J, Smith, G, Koschmieder, S, BrÜmmendorf, T, Schafhausen, P, Gallipoli, P, Thomson, F, Cong, W, Clark, R, Milojkovic, D, Helgason, V, Foroni, L, NICOLINI, F-E, Holyoake, T & Copland, M 2020, ' A randomised Phase II trial of Hydroxychloroquine and Imatinib versus Imatinib alone for patients with Chronic Myeloid Leukaemia in Major Cytogenetic Response with residual disease ', Leukemia . https://doi.org/10.1038/s41375-019-0700-9
1 In chronic-phase chronic myeloid leukaemia (CP-CML), residual BCR-ABL1+ leukaemia stem cells are 2 responsible for disease persistence despite TKI. Based on in vitro data, CHOICES (CHlorOquine and 3 Imatinib Combination to Eliminate Stem cells) was
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24af8c15119e8a2c9bc14fffc509365b
http://europepmc.org/articles/PMC7224085
Zobrazit plný text záznamu
3
Multiple myeloma: therapeutic delivery of antibodies and aptamers
Autor: Paul A. Mulheran, Mohammed M. Al Qaraghuli, Karina Kubiak-Ossowska, Valerie A. Ferro, Neret Pujol-Navarro, Elpiniki Paspali, Gillian A. Horne, Mark Williams, Richard Soutar, Manal Alsaadi
Publikováno v: Therapeutic delivery. 12(10)
Multiple myeloma is the second most common hematological malignancy in adults, accounting for 2% of all cancer-related deaths in the UK. Current chemotherapy-based regimes are insufficient, as most patients relapse and develop therapy resistance. Thi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fdf6be9225a614462c79d65e98a9c33
https://pubmed.ncbi.nlm.nih.gov/34569269
Zobrazit plný text záznamu
5
Haematological problems in the intensive care unit
Autor: Katherine L. McDowall, Gillian A. Horne, Katrina Parsons
Publikováno v: Anaesthesia & Intensive Care Medicine. 20:19-24
Patients admitted to the intensive care unit can be affected by a range of haematological problems, either as a consequence of primary haematological disease or, more commonly, with haematological problems arising as a consequence of other disease pr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34f0f923198fe7a57370a39c73424dd6
https://doi.org/10.1016/j.mpaic.2018.11.008
Zobrazit plný text záznamu
6
Synergistic cytotoxicity of dual PI3K/mTOR and FLT3 inhibition in FLT3-ITD AML cells
Autor: Xu Huang, Manuela Zavatti, Heather G. Jørgensen, Carla Palumbo, Salihanur Darici, Benedetta Accordi, Lucia Manzoli, Luca Braglia, Valentina Serafin, Sandra Marmiroli, Gillian A. Horne
Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy, characterized by a heterogeneous genetic landscape and complex clonal evolution, with poor outcomes. Mutation at the internal tandem duplication of FLT3 (FLT3-ITD) is one of the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21e307afed5aa81a4b91913d02a0c9a3
https://hdl.handle.net/11380/1253717
Zobrazit plný text záznamu
9
Stem Cell Guardians – Old and New Perspectives in LSC Biology
Autor: Tessa L. Holyoake, Lorna Jackson, Vignir G Helgason, Gillian A. Horne
Publikováno v: Current Drug Targets. 18:405-413
The introduction of tyrosine kinase inhibitors in chronic myeloid leukaemia (CML) has revolutionised disease outcome. However, despite this, progression to blast phase disease is high in those that do not achieve complete cytogenetic and major molecu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ae171d78e8e17d43b38e8bb390ea56b
https://doi.org/10.2174/1389450117666160712092944
Zobrazit plný text záznamu
10
Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence
Autor: Xu Huang, Sandra Marmiroli, Hazem Alkhaldi, Gillian A. Horne, Heather G. Jørgensen, Salihanur Darici
Publikováno v: Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 9, Iss 2934, p 2934 (2020)
Acute myeloid leukemia (AML) is a highly heterogeneous hematopoietic malignancy characterized by excessive proliferation and accumulation of immature myeloid blasts in the bone marrow. AML has a very poor 5-year survival rate of just 16% in the UK; h
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55dee6f84ce3141a48807fa1f9fd7eef
https://doi.org/10.3390/jcm9092934
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje